Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

Completed

• Conditions: Enterobacteriaceae Infections

• Registration Number: NCT00573521
• Lead Sponsor: University of Pittsburgh

Brief Summary

This research will be conducted to determine whether risk factors exist for piperacillin/tazobactam resistance in ESBL organisms.

Detailed Description

This is chart review at UPMC. NO human subject interaction will occur.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2007-11
• Study First Submitted: 2007-12-12
• Study First Submitted QC: 2007-12-13
• Study First Posted: 2007-12-14
• Primary Completion: 2017-06
• Study Completion: 2017-06
• Status Verified: 2018-06
• Last Update Submitted: 2018-06-11
• Last Update Posted: 2018-06-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

• Clinical information is collected by chart review of "case" and "control" patients.
• A "case A" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam resistant.
• A "case B" patient is defined as follows: One or more clinical cultures are positive for an ESBL producing bacteria and the organism is piperacillin/tazobactam susceptible.
• Additionally, 1 control patient in the hospital at the same time as the case patients will be randomly selected for each case and are not in either case group.

Read More

Exclusion Criteria

• Patients < 18 years of age

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
This research will help to identify risk factors for resistance to an antibiotic that is commonly used in the empiric treatment of critically ill patients.	2 years

Trial Locations

Locations (1)

UPMC; 🇺🇸 Pittsburgh, Pennsylvania, United States